Edition:
United States

Health News

Photo

AstraZeneca's immunotherapy drug wins key lung cancer approval Feb 19 2018

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

More Headlines

Preemies and underweight babies more likely to have low IQs

(Reuters Health) - Babies who are born much too soon or who arrive weighing too little may not score as high on intelligence tests during childhood as full-term infants, a research review suggests.

Feb 19 2018

New acne diagnoses linked to increased depression risk

(Reuters Health) - In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population, a new study shows.

Feb 19 2018
Photo

Novartis readies to auction U.S. generic pills business: sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

Feb 16 2018

U.S. faces shortage of developmental and behavioral pediatrics specialists

(Reuters Health) - A shortage of clinicians specializing in pediatric behavioral and developmental disorders is translating into long wait times for new patient appointments amid surging demand, a new study suggests.

Feb 16 2018

Health Watch Graphics